Opiates, Serum or Plasma, Quantitative
Ordering Recommendation

Monitor patient adherence.

Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Mon, Wed, Fri
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA). 
Specimen Preparation
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens. 
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years 
Reference Interval
Effective August 17, 2015
Drugs CoveredCutoff Concentrations
Codeine2 ng/mL
Morphine2 ng/mL
6-acetylmorphine2 ng/mL
Hydrocodone2 ng/mL
Hydromorphone2 ng/mL
Oxycodone2 ng/mL
Oxymorphone2 ng/mL

Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff: 2 ng/mL

For medical purposes only; not valid for forensic use.

Identification of specific drug(s) taken by specimen donor is problematic due to common metabolites, some of which are prescriptions drugs themselves. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. All drugs covered are the non-glucuronidated (free) form. The concentration value must be greater than or equal to the cutoff to be reported as positive. A very small amount of an unexpected drug analyte in the presence of a large amount of an expected drug analyte may reflect pharmaceutical impurity. Interpretive questions should be directed to the laboratory.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
View Hotline History
CPT Code(s)
Component Test Code*Component Chart NameLOINC
2006559Hydrocodone, S/P, Quant3680-6
2006560Hydromorphone, S/P, Quant3683-0
2006561Codeine, S/P, Quant3506-3
2006562Morphine, S/P, Quant3827-3
20065636-acetylmorphine, S/P, Quant12788-6
2006564Oxycodone, S/P, Quant3893-5
2006565Oxymorphone, S/P, Quant60467-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Codeine
  • Codeine and Metabolite
  • Dilaudid
  • Heroin
  • Hydrocodone and Metabolite
  • Hydromorphone
  • Morphine
  • MS Contin
  • Norco
  • Opana
  • Opiates Quantitation
  • Oxycodone
  • Oxycodone and Metabolite
  • OxyContin
  • Oxymorphone
  • Pain Management
  • Percocet
  • Percodan
  • Roxicet
  • Roxiprin
  • Tylox